To promote the capitalization and industrialization of pharmaceutical innovative achievements, encourage more investment to Chinese pharmaceutical innovation industry, facilitate the timely transformation of unmet clinical needs, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China Association for Medical Devices Industry (CAMDI) and Hong Kong Exchange and Clearing Limited (HKEX) will hold the 2018 China BioMed Innovation and Investment Conference (2018 CBIIC) in Suzhou Industrial Park on September 18-20. View more
China BioMed Innovation and Investment Conference (CBIIC) was established on November 14, 2016 by China Pharmaceutical Innovation and Research Development Association (PhIRDA), China Association for Medical Devices Industry (CAMDI) and Hong Kong Exchange and Clearing Limited (HKEX).
To promote the capitalization and industrialization of pharmaceutical innovative achievements, encourage more investment to Chinese pharmaceutical innovation industry, facilitate the timely transformation of unmet clinical needs, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China Association for Medical Devices Industry (CAMDI) and Hong Kong Exchange and Clearing Limited (HKEX) will hold the 2018 China BioMed Innovation and Investment Conference (2018 CBIIC) in Suzhou Industrial Park on September 18-20.
The 2018 CBIIC will set various parallel sessions and roadshows, 2 new parallel sessions: the Artificial Intelligence Roadshow and Rare Disease and Orphan Drugs Roadshow, together with Opening Ceremony, Clinical Data Release, International Roadshows, Medical Devices Roadshows, Analysis on the Latest Pharmaceutical Policies Forum and Investors’ Experience Sharing Forum, more than 10 parallel sessions will be shown in this event. To accelerate the process of the integration of pharmaceutical innovation and social capital, hosts of 2018 CBIIC will optimize respective advantages, making it the most internationally influential event of pharmaceutical innovation and investment in Asia.